FLGT
Fulgent Genetics, Inc.
Next earnings Jul 30, 2026 (before open) · consensus $-0.47 EPS, $95.9M rev
Last earnings -7.0% on 2026-05-01
$19.96
▲ +2.67%$19.96▲ +2.20%
over 1Y
L $13.79EODHDH $30.85
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.7%
1W+11.9%
1M+11.5%
3M+28.0%
YTD-22.0%
1Y+2.2%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Revenue grew 13.8% YoY; but unprofitable (net margin -18.8%).
Fulgent Genetics, Inc. shows $323M in FY2025 revenue (+13.8% YoY), a -18.8% net margin, and -5.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $993M | $619M | $289M | $283M | $323M |
| Gross profit | $777M | $367M | $104M | $107M | $131M |
| Operating income | $676M | $179M | -$196M | -$73.9M | -$91.1M |
| Net income | $507M | $143M | -$168M | -$42.7M | -$60.5M |
| Diluted EPS | — | — | — | — | — |
| Net margin | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$573M
EV / EBITDA—
EV / Sales1.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-9.7%
FCF yield-19.9%
Quality & risk
ROIC (est.)-6.5%
Free cash flow-$124M
Total debt—
Net cash$50.2M
Altman Z-Score4.59 safe
Piotroski F-Score3/8
Capital returns
Buyback yield1.7%
Dividend yield (est.)—
Shareholder yield1.7%
Shares Δ YoY+1.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-022026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-022026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗144Filing2026-06-02open ↗8-KPeriod ending 2026-06-012026-06-02open ↗4Period ending 2026-05-272026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-272026-05-28open ↗SCHEDULE 13D/AFiling2026-05-27open ↗4Period ending 2026-05-262026-05-27open ↗8-KPeriod ending 2026-05-212026-05-21open ↗
Frequently asked
- Is Fulgent Genetics, Inc. (FLGT) a buy?
- FLGT currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 13.8% YoY; but unprofitable (net margin -18.8%).
- What is Fulgent Genetics, Inc.'s quality score?
- FLGT scores 52.88235294117647/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001674930, latest 10-Q filed 2026-05-01) · EODHD · as of 6/26/2026, 7:15:21 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.